TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01050036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: 1. Autologous peripheral blood stem cell (PBSCs) harvesting~   * After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~  * Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~  * Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~2. Conditioning regimen for autologous HCT~   * Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~  * Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~3. Autologous cell infusion and waiting for engraftment
Study: NCT00551239

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT01189240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01422733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg/m2/per day PO at bedtime (X12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 1 mg PO twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: 250 micrograms IV twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: 25 mcg IV twice
Study: NCT03350022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Feeding
Description: Sham feeding will be offered to participants.
Study: NCT04453566

Intervention type: OTHER
Intervention: Online Survey
Description: Online Survey
Study: NCT03419663

Intervention type: DIETARY_SUPPLEMENT
Intervention: cereal or grain consumption
Description: intake of cereal, whole grain, refined grain, and other grain of every day
Study: NCT00871169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, oxaliplatin, and cetuximab
Description: Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days.
Study: NCT02499354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol intravenous
Description: IV iron, 2 vials of 510 mg given 2-7 days apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Oral iron, 325 mg tabs taken morning and evening
Study: NCT03828461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group therapy with behavioral practice; 16 weeks
Description: Facilitated group therapy for hoarding disorder with behavioral practice
Study: NCT04179591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intrinsic foot muscles and tibialis posterior strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intrinsic foot muscles and tibialis posterior strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthesis
Description: Customized arch support insoles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthesis
Description: Customized arch support insoles
Study: NCT03035227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmics
Description: Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
Study: NCT00576199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE)
Description: TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE.
Study: NCT02100956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 100 micrograms
Description: oxytocin 100 micrograms administered intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 100 micrograms
Description: oxytocin 100 micrograms administered intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (preservative free)
Description: Normal Saline (preservative free) administered intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (preservative free)
Description: Normal Saline (preservative free) administered intrathecally (IT)
Study: NCT03336632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20 mg orally, twice weekly from D-7 to D+14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/Kg intravenously D+3, +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: 3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
Study: NCT01943461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Study: NCT00943800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)
Description: Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of haploidentical donor, umbilical cord blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of haploidentical donor, umbilical cord blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of haploidentical donor, umbilical cord blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Collections
Description: Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Collections
Description: Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Collections
Description: Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)
Description: Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Busulfan, and ATG
Description: Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
Study: NCT00919958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD IM injection
Description: Single treatment; multiple injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD IM injection
Description: Single treatment; multiple injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD IM injection
Description: Single treatment; multiple injections
Study: NCT02655172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks + PANSS+ IQ
Description: Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
Study: NCT04480099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+X
Description: X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
Study: NCT03314129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UltimEyes
Description: A computer program developed to improve contrast sensitivity and visual acuity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contour Integration Training
Description: A computerized program to improve contour integration (a form of perceptual organization).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UltimEyes + Contour Integration Training
Description: The combination of UltimEyes and Contour Integration Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyBrainSolutions
Description: A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
Study: NCT02311426

Intervention type: OTHER
Intervention: Observational study
Description: Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups

Intervention type: OTHER
Intervention: Observational study
Description: Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
Study: NCT00521898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty (DMEK)
Study: NCT03056326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333 (Part 1 - SAD)
Description: Single doses of CHF6333 at each period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1 - SAD)
Description: Single doses of placebo matching CHF6333 at each period
Study: NCT00551239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone dimaleate
Description: Given IV
Study: NCT00784329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI) System
Description: Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
Study: NCT00634361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoic acid
Description: 2 mg per day
Study: NCT02779920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: per oral pylorotomy
Description: The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
Study: NCT04089631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Study: NCT01730053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study: NCT03056326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333 (Part 2 - MAD)
Description: once daily multiple doses of CHF6333 for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2 - MAD)
Description: once daily multiple doses of placebo matching CHF6333 for 14 days
Study: NCT03016585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Training
Description: Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
Study: NCT03705351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will be given temozolomide according to routine treatment dosing and schedule.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will be given radiation therapy according to routine treatment dosing and schedule.
Study: NCT02415166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA VACCINE
Description: THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA VACCINE
Description: THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl-saline placebo
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl-saline placebo
Description: placebo
Study: NCT02917200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route
Study: NCT01730053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study: NCT00348777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 3 days access to watering place at 6 months
Description: access to watering place for movement in swimming pool, sauna and hammam.
Study: NCT02818452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28XF
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence